think trial: phase i results for nkg2d car-t therapy in aml
Published 5 years ago • 260 plays • Length 4:03Download video MP4
Download video MP3
Similar videos
-
2:49
results of a phase i trial investigating cynk-001, a placental nk-cell product, in patients with aml
-
2:35
quizartinib for frontline flt3-itd aml: updated results from the quantum-first trial
-
3:00
komet-001: targeting menin-kmt2a in aml
-
2:43
gemtuzumab ozogamicin in frontline aml therapy
-
3:31
update on quantum-first: quizartinib soc chemotherapy & as continuation therapy in flt3-itd aml
-
1:11
distinkt trial analysis: efficacy and safety of imc-001 for r/r enktl
-
0:57
potential approval of quizartinib in aml & its place in the aml treatment regimen
-
3:10
novel aml treament approaches
-
10:01
novel targets in 2022
-
5:20
immuno-oncology agents for mm: checkpoint inhibitors and nk-cells
-
2:41
cell avidity as a predictor of t-cell efficacy
-
17:23
updates in cll: key clinical trials in the frontline and r/r setting, pre-clinical data and mrd
-
1:50
progress for gilteritinib and quizartinib for aml in the first-line setting
-
2:08
advances in gene engineering technologies for nk cell-based immunotherapy
-
0:59
next steps for gene-edited nk cells in the treatment of hematological malignancies
-
1:25
preliminary results from a phase ib trial of as-1763, a novel non-covalent btki, in cll/mcl
-
1:40
results from a phase i/ii study of golcadomide in r/r follicular lymphoma
-
1:25
car-t in mm: karmma, cartitude-1 and evolve
-
1:07
quantum-first: the benefit of quizartinib based on pre-transplant mrd status